The Myths and Realities of Prostate Cancer Chemoprevention – A Journey Through Scientific Evidences
Main Article Content
Abstract
The goals of primary chemoprevention of any disease include decreasing the incidence of disease, reducing treatment-related adverse events, cutting down the cost of treatment and bringing down the mortality due to the disease. Increased prevalence of prostate cancer and identification of large numbers of newly detected disease due to the availability of better screening measures, long latency of the disease and peculiar molecular basis of pathogenesis make prostate cancer an attractive target of chemoprevention. This article reviews the experimental and epidemiological data available from 1998 to 2023 on the effectiveness, safety and toxicity of various nutritional and other agents proposed to be used for prostate cancer chemoprevention either to reduce the incidence of this cancer and/or slow down the disease progression. No single agent has been categorically proved to be the best for chemoprevention of prostate cancer as of now. Although majority of studies do not propose adopting chemoprevention in the entire elderly men population, it may be ideal that the men at higher risk of contracting prostate cancer like those having positive family history would be the best choice for implementing chemoprevention.
Keywords:
Prostate Cancer, Chemoprevention, Prostate Cancer Chemoprevention
Article Details
How to Cite
MOORTHY, Dr. H. Krishna; KRISHNAMOORTHY, Dr. Ashwin.
The Myths and Realities of Prostate Cancer Chemoprevention – A Journey Through Scientific Evidences.
Medical Research Archives, [S.l.], v. 11, n. 11, nov. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4645>. Date accessed: 16 may 2024.
doi: https://doi.org/10.18103/mra.v11i11.4645.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk F, Pike M et al. 5 Alpha reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992; 339:887-89
2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993; 118:793-803
3. Brawley OW. The potential for prostate cancer chemoprevention. Rev Urol. 2002; 4(5 Suppl):S11-17
4. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L et al. Chemoprevention of prostate cancer – concepts and strategies. Eur Urol. 1999; 35:342-50
5. Fisher B, Costantino JP, Wickerman DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer – report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371-88
6. Gupta S. Prostate cancer chemoprevention – models, limitations and potential. Int J Oncol. 2004; 25:1133-48
7. Lieberman R. Evolving strategies for prostate cancer chemoprevention trials. World J Urol. 2003; 21(1):1-11
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003; 349(4):366-81.
9. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012; 12(12):835-48
10. Steinmetz KA, Potter JD. Vegetables, fruit and cancer. Epidemiol Cancer Causes Control. 1991; 2:325-57
11. Lowe JF, Lawence A. Update on prostate cancer chemoprevention. Pharmacotherapy. 2006; 26(3):353-59
12. Pascual-Geler M, Urquiza-Salvat N, Cozar JMM, Robles-Fernandez I, Rivas A, Martinez-Gonzalez LJ et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. The Aging Male. 2018; 21(1):31-39 PMID: 28929838. DOI: 10.1080/ 13685538.2017.1379491
13. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am J Epidemiol. 2000; 151:119-23
14. Giovannucci E, Ascherio A, Rimm E, Stampfer M, Colditz G, Eillet W. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995; 87:1767-76
15. Zackheim HS. Tomatoes, tomato based products, lycopene and prostate cancer – review of the epidemiologic literature. J Natl Cancr Inst. 1999; 91:1331
16. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK et al. Effects of alpha tocopherol and beta carotene supplements on cancer incidence in the alpha tocopherol beta carotene cancer prevention study. Am J Clin Nutr. 1995; 62(6 Suppl):1427S-30
17. Ilic D, Forbes KM, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. 2011; (11): CD008007
18. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer – current status. J Natl Cancer Inst. 1999; 91:414-28
19. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene and prostate cancer risk. J Natl Cancer Inst. 2002; 94:391-98
20. Moorthy HK, Venugopal P. Strategies for prostate cancer prevention: Review of the literature. Indian J Urol. 2008; 24(3):295-302
21. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000; 85:60-67
22. Haenszel W, Kurihoro M. Studies of Japanese migrants. J Natl Cancer Inst. 1969; 40:43-68
23. Severson RK, Grove JS, Nomura AM, Stemmerman GN. Body mass and prostatic cancer – a prospective study. BMJ. 1988; 297:713-15
24. Bruning PF, Bonfrer JMG. Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma. Cancer Res. 1989; 46:2606-09
25. Pusateri DJ, Roth WT, Ross JK, Shultz TD. Dietary and hormonal evaluation of men at different risks for prostate cancer – plasma and fecal hormone nutrient interrelationships. Am J Clin Nutr. 1990; 51:371-77
26. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I et al. Projecting Prostate Cancer Mortality in the PCPT and REDUCE Chemoprevention Trials. Cancer. 2013; 119(3):593-601
27. Brown MD, Hart CA, Gazi E, Bagley S, Clarke NW. Promotion of prostatic metastatic migration towards human bone marrow stroma by omega-6 and its inhibition by omega-3 PUFAs. Br J Cancer. 2006;94(6):842-53
28. Brawley OW, Barnes ST. Potential agents for prostate cancer chemoprevention. Epidemiol Rev. 2001; 23(1):168-72
29. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998; 9:553-57
30. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst. 1991; 83:541-46
31. Aldercruetz H, Fotsis T, Schweigerer L. Isofavonoids and 2-methoxyestradiol: inhibitors of tumor cell growth and angiogenesis. Proc Ann Meet Am Assoc Cancer Res. 1994; 35:693-94
32. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995; 147:295-302
33. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostate disease. Eur Urol. 1999; 35:377-87
34. Davis JN, Kucuk O and Sarkar FH. Genistein inhibits NF-Kappa B activation in prostate cancer cells. Nutr Cancer. 1999; 35:167-74
35. Zhang L, Li L, Jiao M, Wu D, Wu D, Wu K et al. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog–Gli1 pathway. Cancer Letters. 2012; 323:48-57
36. Hsu A, Brunob RS, Löhr CV, Taylor AW, Dashwood RH, Bray TM et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκ B pathway in the Noble rat model. J Nutr Biochem. 2011; 22:502-10
37. Klein EA. Can prostate cancer be prevented? Nature. Clin Practice Urol. 2005;2(1):24-31
38. Adhami VM, Ahamad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr. 2003; 133(Suppl):2417S-24S
39. Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Quercetin in prostate cancer – chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential. Oncology Reports. 2015; 33:2659-68
40. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D et al. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015; 75(5):550-59 PMID: 25545744. DOI: 10.1002/pros.22943
41. Skhlar G, Oh SK. Experimental basis for cancer prevention by vitamin E. Cancer Invest 2000; 18:214-22
42. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene – incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998; 90:440-46
43. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999; 8:887-92
44. Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? BJU Int. 2005; 96:231-36
45. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer: retinol, carotenoids and tocopherol and risk of prostate cancer. J Natl Cancer Inst. 1990; 82:941-46
46. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70:2861-69
47. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL et al. Vitamin D related genetic variation, plasma vitamin D and risk of lethal prostate cancer – a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690-99
48. Kumar NB, Besterman-Dahan K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control. 1999;6(5):580-86
49. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999;221:89-98
50. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophy Res Comm. 1985;130:603-09
51. Clark LC, Combs GR Jr, Turnbull BW. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-63
52. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis. 2000;3:145-51
53. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009; 301:52-62
54. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013; 73(3):328-35
55. Song ZY, Yao Q, Zhuo Z, Ma Z, Chen G. Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis. Endocr Connect. 2018; 7(12):R294-R303 doi: 10.1530/EC-18-0283. PMID: 30352424; PMCID: PMC6240137
56. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004; 14:143-49
57. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Anti androgens and 5-alpha-reductase inhibition of the proliferative rate in PC3 and DU145 human prostate cancer cell lines. Current Ther Res. 1992; 51:799-813
58. Delos S, Iehle C, Martin PM, Reynaud JP. Inhibition of the activity of basic 5 alpha reductase (type I) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol. 1994; 48:347-52
59. Goetzl MA, Holzbeierlein JM. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nature Clinical Practice. 2006; 3(8):422-29
60. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89:2179-84
61. Gomella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol. 2005; 15:29-32
62. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379:1103-11
63. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5 α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365(2):97–99
64. Kattan MW, Earnshaw SR, McDade CL, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011; 9(5):305-15
65. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008; 112(5):1058-65
66. Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res. 2011;4(2):277-83
67. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006; 98(16):1128-33
68. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007; 177(5):1749-52
69. Stoner E. Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43:284-92
70. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate carcinoma. Prostate. 2000; 42:73-78
71. Barqawi A, Thompson IM, Crawford ED. Prostate cancer prevention: an overview of United States Trials. J Urol. 2004; 171(Suppl):S5-9
72. Harris RE, Beebe-Donk J, Doss H, Doss DB. Aspirin, ibuprofen and other nonsteroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep. 2005; 13:559-83
73. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004; 90:93-99
74. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012; 23:1403-15
75. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377:31-41
76. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Curr Oncol Rep. 2013; 15:533-40
77. Steiner MS, Raghow S. Antiestrogens and selected estrogen receptor modulators reduce prostate cancer risk. World J Urol. 2003; 21:31-36
78. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steineret M. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013; 31(5):523-29
79. Chen CB, Eurich DT, Majumdar SR, Johnson JA. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study. Prostate Cancer Prostatic Dis. 2017; 20(1):122-126
80. Haggstrom C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017; 140(3):611-17
81. Freedman LS, Agay N, Farmer R, Murad H, Olmer L, Dankner R. Metformin treatment among men with diabetes and the risk of prostate cancer: A population-based historical cohort study. Am J Epidemiol. 2022; 191(4):626-35 https://doi.org/10.1093/aje/kwab287
82. Murtola TJ, Visakorpi T, Lahtela J, Syvala H,Tammela TL. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008; 5(7):376-87
83. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE. 2012; 7(10):e46691
84. Giovannucci E, Clinton SK. Tomatoes, lycopene and prostate cancer. Proc Soc Exp Biol Med.1998; 218:129-39
85. Thompson IM, Coltman CA, Brawley OW, Ryan A. Chemoprevention of prostate cancer. Semin Urol. 1995; 13:122-29
86. Singh DK, Lippman SM. Cancer chemoprevention, Part 2: Hormones non classic antioxidant natural agents, NSAIDs and other agents. Oncology (Huntingt). 1998; 12:1787-800
87. Schmitz-Drager BJ, Eichholzer M, Beiche B, Ebert T. Nutrition and prostate cancer. Urol Int. 2001; 67:1-11
88. Singh RP and Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocrine-Related Cancer. 2006; 13:751-78
89. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Aca Scien USA (PNAS). 2005; 102 (41):14813-18
90. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU 145 cells via caspase activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis. 2002; 23(11):1869-76
91. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. Prostate Cancer Prostatic Dis. 2000; 3:84-93
92. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in prostate cancer-III. Prostate. 2001;47:293-303
93. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in prostate cancer-II. Mol Urol. 2000; 4:1-6
94. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. The AAP Jour. 2006; 8(3):443-49
95. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Nihal A. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma ells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther. 2004; 3:933-40
96. Schoonen WM, Salinas CA, Kiemeney ALM, Stanford JL. Alcohol consumption and risk of prostate cancer in middle aged men. Int J Cancer. 2005; 113:133-40
97. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Millet WC. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12:1403-09
98. Venier NA, Yamamoto T, Sugar LM, Adomat H, Fleshner NE, Klotz LH et al. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model. Prostate. 2015;75(12):1300-11
99. Xing N, Chen Y, Mitchell SH , Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001; 22:409-14
100. Wang G, Song L, Wang H, Xing N. Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells. Oncol Rep. 2013; 30:357-63
101.Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Quercetin in prostate cancer- chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential. Oncology Reports. 2015;33:2659-68
102. Sharmila G, Bhat FA, Arunkumar R, Elumalai P, Raja Singh P, Senthilkumar K et al. Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr. 2014; 33:718-26
103. Firdous AB, Sharmila G, Balakrishnan S, RajaSingh P, Suganya S, Srinivasan N et al. Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food Funct. 2014; 5: 2632-45
104. Sharmila G, Athirai T, Kiruthiga B, Senthilkumar K, Elumalai P, Arunkumar R et al. Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats. Nutr Cancer. 2014; 66:38-46
105. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Induction of prostate cancer cell apoptosis with Zyflamend. Nutr Cancer. 2005; 52(2):202-12
106. Keogh JWL, McLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. J Pain Symptom Manage. 2012; 43:96-110
107. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA , McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol. 2016; 70(4):576-85
108. Galvao DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP et al. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol. 2016; 13(5):258-65
109. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011; 29(6):726-32
110. Orsini N, Bellocco R, Bottai M, Pagano M, Andersson SO, Johansson JE et al. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer. 2009; 101(11):1932-38
111. Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol. 2017; 27(5):415-21
112. Hayes SC, Newton RU, Spence RR, Galvao DA. The Exercise and Sports Science Australia position statement: exercise medicine in cancer management. J Sci Med Sport. 2019; 22(11):1175-99 10.1016/ j.jsams.2019.05.003
113. Barrington WE, Schenk JM, Etzioni R, Arnold KB,Neuhouser ML,Jr IMT et al. Difference in association of obesity with prostate cancer risk between US African American and non Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015;1(3):342-49
114. Cao Y, Ma J. Body-mass index, prostate cancer-specific mortality and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4(4):486-501
115. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011; 305(24):2548-55
116. Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023; 21:19 doi: 10.18332/tid/157231. PMID: 36762260; PMCID: PMC9900478
117. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016; 70(6):974-82 doi: 10.1016/j.eururo.2016.03.027. Epub 2016 Mar 28. PMID: 27033442; PMCID: PMC5040619
118. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res.1994; 54:1760-65
119. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Clift BM et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006; 121:3394-401
120. Higano CS, Corman JM, Smith DC, Centeno AS, steidle CP, Gittleman M et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008; 113:975-84
121. Drake CG. Immunotherapy for prostate cancer: walk, don’t run. J Clin Oncol. 2009; 27:4035-37
122. Sadde F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines. 2012; 11:189-209
123. Liu J, Li Y, Yang D, Yang C, Mao L. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer. Discov Med. 2019; 27(150):235-43
124. Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol Immunother. 2020; 69(5):847-57
125. Wang J, Zhou K, Zhu H, Wei F, Ma S, Kan Y et al. Current status and progress of the development of prostate cancer vaccines. J Cancer. 2023; 14(5):835-42 doi: 10.7150/ jca.80803. PMID: 37056394; PMCID: PMC10088880
126. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17(11):3520-26
127. Maiorano BA, Schinzari G, Ciardiello D, Rodriquenz MG, Cisternino A, Tortora G et al. Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines (Basel). 2021; 9(6):623
128. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22 https://pubmed.ncbi.nlm.nih.gov/20818862/
129. EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6
130. Varisli L, Tolan V, Cen JH, Vlahopoulos S, Cen O. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. Oncol Res. 2022; 30(3):137-55
131. Montironi R, Mazzucchelli R, Algaba F, Lopez-Beltran A. Morphological identification of the patterns of prostate intraepithelial neoplasia and their importance. J Clin Pathol. 2000; 53:655-65
132. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Eng J Med. 2001; 344:1373-77
133. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ideda K, Urano T et al. Identification of novel androgen response genes in prostatic cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene. 2007; 26:4453-63
134. Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A et al. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU Int. 2004; 93:955-60
135. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Molecular Therapy. 2007; 15(3):1016-23.
2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993; 118:793-803
3. Brawley OW. The potential for prostate cancer chemoprevention. Rev Urol. 2002; 4(5 Suppl):S11-17
4. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L et al. Chemoprevention of prostate cancer – concepts and strategies. Eur Urol. 1999; 35:342-50
5. Fisher B, Costantino JP, Wickerman DL, Redmond CK, Kavanah M, Cronin WM et al. Tamoxifen for prevention of breast cancer – report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90:1371-88
6. Gupta S. Prostate cancer chemoprevention – models, limitations and potential. Int J Oncol. 2004; 25:1133-48
7. Lieberman R. Evolving strategies for prostate cancer chemoprevention trials. World J Urol. 2003; 21(1):1-11
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003; 349(4):366-81.
9. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012; 12(12):835-48
10. Steinmetz KA, Potter JD. Vegetables, fruit and cancer. Epidemiol Cancer Causes Control. 1991; 2:325-57
11. Lowe JF, Lawence A. Update on prostate cancer chemoprevention. Pharmacotherapy. 2006; 26(3):353-59
12. Pascual-Geler M, Urquiza-Salvat N, Cozar JMM, Robles-Fernandez I, Rivas A, Martinez-Gonzalez LJ et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. The Aging Male. 2018; 21(1):31-39 PMID: 28929838. DOI: 10.1080/ 13685538.2017.1379491
13. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am J Epidemiol. 2000; 151:119-23
14. Giovannucci E, Ascherio A, Rimm E, Stampfer M, Colditz G, Eillet W. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995; 87:1767-76
15. Zackheim HS. Tomatoes, tomato based products, lycopene and prostate cancer – review of the epidemiologic literature. J Natl Cancr Inst. 1999; 91:1331
16. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK et al. Effects of alpha tocopherol and beta carotene supplements on cancer incidence in the alpha tocopherol beta carotene cancer prevention study. Am J Clin Nutr. 1995; 62(6 Suppl):1427S-30
17. Ilic D, Forbes KM, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. 2011; (11): CD008007
18. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer – current status. J Natl Cancer Inst. 1999; 91:414-28
19. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene and prostate cancer risk. J Natl Cancer Inst. 2002; 94:391-98
20. Moorthy HK, Venugopal P. Strategies for prostate cancer prevention: Review of the literature. Indian J Urol. 2008; 24(3):295-302
21. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000; 85:60-67
22. Haenszel W, Kurihoro M. Studies of Japanese migrants. J Natl Cancer Inst. 1969; 40:43-68
23. Severson RK, Grove JS, Nomura AM, Stemmerman GN. Body mass and prostatic cancer – a prospective study. BMJ. 1988; 297:713-15
24. Bruning PF, Bonfrer JMG. Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma. Cancer Res. 1989; 46:2606-09
25. Pusateri DJ, Roth WT, Ross JK, Shultz TD. Dietary and hormonal evaluation of men at different risks for prostate cancer – plasma and fecal hormone nutrient interrelationships. Am J Clin Nutr. 1990; 51:371-77
26. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I et al. Projecting Prostate Cancer Mortality in the PCPT and REDUCE Chemoprevention Trials. Cancer. 2013; 119(3):593-601
27. Brown MD, Hart CA, Gazi E, Bagley S, Clarke NW. Promotion of prostatic metastatic migration towards human bone marrow stroma by omega-6 and its inhibition by omega-3 PUFAs. Br J Cancer. 2006;94(6):842-53
28. Brawley OW, Barnes ST. Potential agents for prostate cancer chemoprevention. Epidemiol Rev. 2001; 23(1):168-72
29. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998; 9:553-57
30. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst. 1991; 83:541-46
31. Aldercruetz H, Fotsis T, Schweigerer L. Isofavonoids and 2-methoxyestradiol: inhibitors of tumor cell growth and angiogenesis. Proc Ann Meet Am Assoc Cancer Res. 1994; 35:693-94
32. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol. 1995; 147:295-302
33. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostate disease. Eur Urol. 1999; 35:377-87
34. Davis JN, Kucuk O and Sarkar FH. Genistein inhibits NF-Kappa B activation in prostate cancer cells. Nutr Cancer. 1999; 35:167-74
35. Zhang L, Li L, Jiao M, Wu D, Wu D, Wu K et al. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog–Gli1 pathway. Cancer Letters. 2012; 323:48-57
36. Hsu A, Brunob RS, Löhr CV, Taylor AW, Dashwood RH, Bray TM et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκ B pathway in the Noble rat model. J Nutr Biochem. 2011; 22:502-10
37. Klein EA. Can prostate cancer be prevented? Nature. Clin Practice Urol. 2005;2(1):24-31
38. Adhami VM, Ahamad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr. 2003; 133(Suppl):2417S-24S
39. Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Quercetin in prostate cancer – chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential. Oncology Reports. 2015; 33:2659-68
40. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D et al. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015; 75(5):550-59 PMID: 25545744. DOI: 10.1002/pros.22943
41. Skhlar G, Oh SK. Experimental basis for cancer prevention by vitamin E. Cancer Invest 2000; 18:214-22
42. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene – incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998; 90:440-46
43. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999; 8:887-92
44. Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? BJU Int. 2005; 96:231-36
45. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer: retinol, carotenoids and tocopherol and risk of prostate cancer. J Natl Cancer Inst. 1990; 82:941-46
46. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer. 1992; 70:2861-69
47. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL et al. Vitamin D related genetic variation, plasma vitamin D and risk of lethal prostate cancer – a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690-99
48. Kumar NB, Besterman-Dahan K. Nutrients in the chemoprevention of prostate cancer: current and future prospects. Cancer Control. 1999;6(5):580-86
49. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999;221:89-98
50. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophy Res Comm. 1985;130:603-09
51. Clark LC, Combs GR Jr, Turnbull BW. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957-63
52. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis. 2000;3:145-51
53. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009; 301:52-62
54. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013; 73(3):328-35
55. Song ZY, Yao Q, Zhuo Z, Ma Z, Chen G. Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis. Endocr Connect. 2018; 7(12):R294-R303 doi: 10.1530/EC-18-0283. PMID: 30352424; PMCID: PMC6240137
56. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004; 14:143-49
57. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Anti androgens and 5-alpha-reductase inhibition of the proliferative rate in PC3 and DU145 human prostate cancer cell lines. Current Ther Res. 1992; 51:799-813
58. Delos S, Iehle C, Martin PM, Reynaud JP. Inhibition of the activity of basic 5 alpha reductase (type I) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol. 1994; 48:347-52
59. Goetzl MA, Holzbeierlein JM. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nature Clinical Practice. 2006; 3(8):422-29
60. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89:2179-84
61. Gomella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol. 2005; 15:29-32
62. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379:1103-11
63. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5 α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365(2):97–99
64. Kattan MW, Earnshaw SR, McDade CL, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011; 9(5):305-15
65. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008; 112(5):1058-65
66. Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res. 2011;4(2):277-83
67. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006; 98(16):1128-33
68. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007; 177(5):1749-52
69. Stoner E. Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994; 43:284-92
70. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate carcinoma. Prostate. 2000; 42:73-78
71. Barqawi A, Thompson IM, Crawford ED. Prostate cancer prevention: an overview of United States Trials. J Urol. 2004; 171(Suppl):S5-9
72. Harris RE, Beebe-Donk J, Doss H, Doss DB. Aspirin, ibuprofen and other nonsteroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep. 2005; 13:559-83
73. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer. 2004; 90:93-99
74. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012; 23:1403-15
75. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377:31-41
76. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Curr Oncol Rep. 2013; 15:533-40
77. Steiner MS, Raghow S. Antiestrogens and selected estrogen receptor modulators reduce prostate cancer risk. World J Urol. 2003; 21:31-36
78. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steineret M. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol. 2013; 31(5):523-29
79. Chen CB, Eurich DT, Majumdar SR, Johnson JA. Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study. Prostate Cancer Prostatic Dis. 2017; 20(1):122-126
80. Haggstrom C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L et al. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017; 140(3):611-17
81. Freedman LS, Agay N, Farmer R, Murad H, Olmer L, Dankner R. Metformin treatment among men with diabetes and the risk of prostate cancer: A population-based historical cohort study. Am J Epidemiol. 2022; 191(4):626-35 https://doi.org/10.1093/aje/kwab287
82. Murtola TJ, Visakorpi T, Lahtela J, Syvala H,Tammela TL. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008; 5(7):376-87
83. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE. 2012; 7(10):e46691
84. Giovannucci E, Clinton SK. Tomatoes, lycopene and prostate cancer. Proc Soc Exp Biol Med.1998; 218:129-39
85. Thompson IM, Coltman CA, Brawley OW, Ryan A. Chemoprevention of prostate cancer. Semin Urol. 1995; 13:122-29
86. Singh DK, Lippman SM. Cancer chemoprevention, Part 2: Hormones non classic antioxidant natural agents, NSAIDs and other agents. Oncology (Huntingt). 1998; 12:1787-800
87. Schmitz-Drager BJ, Eichholzer M, Beiche B, Ebert T. Nutrition and prostate cancer. Urol Int. 2001; 67:1-11
88. Singh RP and Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocrine-Related Cancer. 2006; 13:751-78
89. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Aca Scien USA (PNAS). 2005; 102 (41):14813-18
90. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU 145 cells via caspase activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis. 2002; 23(11):1869-76
91. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. Prostate Cancer Prostatic Dis. 2000; 3:84-93
92. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in prostate cancer-III. Prostate. 2001;47:293-303
93. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in prostate cancer-II. Mol Urol. 2000; 4:1-6
94. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. The AAP Jour. 2006; 8(3):443-49
95. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Nihal A. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma ells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer Ther. 2004; 3:933-40
96. Schoonen WM, Salinas CA, Kiemeney ALM, Stanford JL. Alcohol consumption and risk of prostate cancer in middle aged men. Int J Cancer. 2005; 113:133-40
97. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Millet WC. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12:1403-09
98. Venier NA, Yamamoto T, Sugar LM, Adomat H, Fleshner NE, Klotz LH et al. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model. Prostate. 2015;75(12):1300-11
99. Xing N, Chen Y, Mitchell SH , Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001; 22:409-14
100. Wang G, Song L, Wang H, Xing N. Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells. Oncol Rep. 2013; 30:357-63
101.Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Quercetin in prostate cancer- chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential. Oncology Reports. 2015;33:2659-68
102. Sharmila G, Bhat FA, Arunkumar R, Elumalai P, Raja Singh P, Senthilkumar K et al. Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clin Nutr. 2014; 33:718-26
103. Firdous AB, Sharmila G, Balakrishnan S, RajaSingh P, Suganya S, Srinivasan N et al. Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food Funct. 2014; 5: 2632-45
104. Sharmila G, Athirai T, Kiruthiga B, Senthilkumar K, Elumalai P, Arunkumar R et al. Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats. Nutr Cancer. 2014; 66:38-46
105. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Induction of prostate cancer cell apoptosis with Zyflamend. Nutr Cancer. 2005; 52(2):202-12
106. Keogh JWL, McLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: A systematic review. J Pain Symptom Manage. 2012; 43:96-110
107. Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA , McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol. 2016; 70(4):576-85
108. Galvao DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP et al. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nat Rev Urol. 2016; 13(5):258-65
109. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011; 29(6):726-32
110. Orsini N, Bellocco R, Bottai M, Pagano M, Andersson SO, Johansson JE et al. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer. 2009; 101(11):1932-38
111. Bandini M, Gandaglia G, Briganti A. Obesity and prostate cancer. Curr Opin Urol. 2017; 27(5):415-21
112. Hayes SC, Newton RU, Spence RR, Galvao DA. The Exercise and Sports Science Australia position statement: exercise medicine in cancer management. J Sci Med Sport. 2019; 22(11):1175-99 10.1016/ j.jsams.2019.05.003
113. Barrington WE, Schenk JM, Etzioni R, Arnold KB,Neuhouser ML,Jr IMT et al. Difference in association of obesity with prostate cancer risk between US African American and non Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015;1(3):342-49
114. Cao Y, Ma J. Body-mass index, prostate cancer-specific mortality and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011; 4(4):486-501
115. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011; 305(24):2548-55
116. Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023; 21:19 doi: 10.18332/tid/157231. PMID: 36762260; PMCID: PMC9900478
117. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016; 70(6):974-82 doi: 10.1016/j.eururo.2016.03.027. Epub 2016 Mar 28. PMID: 27033442; PMCID: PMC5040619
118. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res.1994; 54:1760-65
119. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Clift BM et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006; 121:3394-401
120. Higano CS, Corman JM, Smith DC, Centeno AS, steidle CP, Gittleman M et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008; 113:975-84
121. Drake CG. Immunotherapy for prostate cancer: walk, don’t run. J Clin Oncol. 2009; 27:4035-37
122. Sadde F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines. 2012; 11:189-209
123. Liu J, Li Y, Yang D, Yang C, Mao L. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer. Discov Med. 2019; 27(150):235-43
124. Noguchi M, Arai G, Egawa S, Ohyama C, Naito S, Matsumoto K et al. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol Immunother. 2020; 69(5):847-57
125. Wang J, Zhou K, Zhu H, Wei F, Ma S, Kan Y et al. Current status and progress of the development of prostate cancer vaccines. J Cancer. 2023; 14(5):835-42 doi: 10.7150/ jca.80803. PMID: 37056394; PMCID: PMC10088880
126. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17(11):3520-26
127. Maiorano BA, Schinzari G, Ciardiello D, Rodriquenz MG, Cisternino A, Tortora G et al. Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines (Basel). 2021; 9(6):623
128. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22 https://pubmed.ncbi.nlm.nih.gov/20818862/
129. EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6
130. Varisli L, Tolan V, Cen JH, Vlahopoulos S, Cen O. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. Oncol Res. 2022; 30(3):137-55
131. Montironi R, Mazzucchelli R, Algaba F, Lopez-Beltran A. Morphological identification of the patterns of prostate intraepithelial neoplasia and their importance. J Clin Pathol. 2000; 53:655-65
132. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Eng J Med. 2001; 344:1373-77
133. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ideda K, Urano T et al. Identification of novel androgen response genes in prostatic cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene. 2007; 26:4453-63
134. Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A et al. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU Int. 2004; 93:955-60
135. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Molecular Therapy. 2007; 15(3):1016-23.